MedTrace Logo

Efficacy of Bifeprunox in Patients With Schizophrenia

NCT00704509 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 346

Last updated 2010-09-27

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.

Conditions

Interventions

DRUG

Bifeprunox

20 mg daily, encapsulated tablets, orally, 12 months

DRUG

Placebo

Encapsulated tablets, orally, 12 weeks

DRUG

Quetiapine

600 mg daily, encapsulated tablets, orally, 12 months

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-08-31
Completion
2009-11-30

Countries

  • India
  • Indonesia
  • Malaysia
  • Philippines
  • Poland
  • South Korea
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704509 on ClinicalTrials.gov